Statin withdrawal: Clinical implications and molecular mechanisms

Pharmacotherapy

Volumn 26, Issue 9 I, 2006, Pages 1288-1296

  Cubeddu, Luigi X ^a   Seamon, Matthew J ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; HMG CoA reductase inhibitors; Cardiovascular risk; Statin withdrawal; Statins

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ATORVASTATIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHOLESTEROL; CITRULLINE; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; FLUINDOSTATIN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PADGEM PROTEIN; PROCOAGULANT; RAC PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; SYNAPTOPHYSIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ATHEROSCLEROTIC PLAQUE; CARDIOGENIC SHOCK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CORONARY RISK; DATA ANALYSIS; DEATH; DISEASE EXACERBATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIVER TOXICITY; LUNG EDEMA; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; MYALGIA; MYOSITIS; NONHUMAN; REGISTER; RETROSPECTIVE STUDY; REVIEW; RHABDOMYOLYSIS; SHOCK; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; WITHDRAWAL SYNDROME;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; WITHHOLDING TREATMENT;

EID: 33748100587     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.9.1288     Document Type: Review

References (49)

1. Thom T, Haase N, Rosamond W, et al, for the American Heart Association. Heart disease and stroke statistics-2006 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2006;113:e85-151. Available from http://circ.ahajournals.org/cgi/ content/full/113/6/e85.
2. (Erratum in Circulation 2006;113(14):e696.)
3. Yusuf HR, Giles WH, Croft JB, Anda RF, Casper ML. Impact of multiple risk factor profiles on determining cardiovascular disease risk. Prev Med 1998;27(1):1-9.
4. Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995;333:1301-7.
6. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332 (8):512-21.
7. Farmer JA, Gotto AM Jr. Current and future therapeutic approaches to hyperlipidemia. Adv Pharmacol 1996;35:79-114.
8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Engl J Med 1996;335(14):1001-9.
9. The LIPID Investigators. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the long-term intervention with pravastatin in ischaemic disease (LIPID) study group. N Engl J Med 1998;339 (19):1349-57.
10. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of CAPS/TexCAPS: Air Force/Texas coronary atherosclerosis prevention study. JAMA 1998;279(20):1615-22.
11. Stein E A. The power of statins: aggressive lipid lowering. Clin Cardiol 2003;26(4 suppl 3):III25-31.
12. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101(2):207-13.
13. Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J 2003;145(3):387-96.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2002;285:2486-97.
15. Conti CR. Evolution of NCEP guidelines: ATPI-ATPIII risk estimation for coronary heart disease in 2002. National cholesterol education program. Clin Cardiol 2002;25(3):89-90.
16. Vaughan C, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
17. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289(13):1681-90.
18. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004;147:956-65.
19. Fuhrmans V. Bayer discloses higher death toll from Baycol. Wall Street Journal January 21, 2002:A10.
20. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003;163(6):688-92.
21. Simons LA, Simons J, McManus P, Dudley J. Discontinuation rates for use of statins are high [letter]. BMJ 2000;321(7268):1084.
22. Thomas M, Mann J. Increased thrombotic vascular events after change of statin [letter]. Lancet 1998;352:1830-1.
23. Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000;102(25):3104-10.
24. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 2002;91:173-9.
25. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD, for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105(12):1446-52.
26. Heeschen C, Hamm CW, Laufs U, Bohm M, Snapinn S, White HD. Withdrawal of statins in patients with acute coronary syndromes [letter]. Circulation 2003;107:27.
27. Spencer FA, Fonarow GC, Frederick PD, et al, for the National Registry of Myocardial Infarction. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med 2004;164(19):2162-8.
28. Spencer FA, Allegrone J, Goldberg RJ, et al, for the GRACE Investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004;140(11):857-66.
29. McGowan MD. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004;110:2333-5.
30. Schwartz GG, Olsson AG, Ezekowitz MD, et al, for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285(13):1711-18.
31. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002;22:1524-34.
32. Kinlay S, Schwartz GG, Olsson AG, et al, for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study. Circulation 2004;110:386-91.
33. Ray KK, Cannon CP. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol 2004;15(6):637-43.
34. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bohm M, Nickening G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001;88(11):1306-7.
35. Lee KT, Lai WT, Chu CS, et al. Effect of withdrawal of statin on C-reactive protein. Cardiology 2004;102(3):166-70.
36. Puccetti L, Pasqui AL, Pastorelli M, et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost 2003;90:476-82.
37. Brandes RP, Beer S, Ha T, Busse R. Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23(10):1794- 800.
38. Gertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003;34(2):551-7.
39. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997;17:265-72.
40. Ni W, Egashira K, Kitamoto S, et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001;103:2096-101.
41. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000;52(4):639-72.
42. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten. J Am Coll Cardiol 2005;45(8):1287-91.
43. Laufs U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res 2000;87(7):526-8.
44. Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001;21(12):1896-901.
45. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001;59(3):646-54.
46. Sah VP, Minamisawa S, Tam SP, et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest 1999;103(12):1627-34.
47. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999;274 (31):21926-31.
48. Blanco-Colio LM, Villa A, Ortego M, et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002;161(1):17-26.
49. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004;35(11 suppl 1):2708-11.